Skip to main content English

Detail

Yen Y. Tan
Priv. Doz. Yen Y. Tan, PhD MSc BScPrincipal Investigator

Department of Obstetrics and Gynecology
Position: Associate Professor

ORCID: 0000-0003-1063-5352
yen.tan@meduniwien.ac.at

Keywords

Hereditary Breast and Ovarian Cancer Syndrome; Molecular Epidemiology

Research interests

  • Hereditary breast and ovarian cancers
  • Translational cancer epidemiology
  • Variant interpretation and risk stratification in BRCA1/2 (and associated genes) carriers
  • Psychosocial and long-term health outcomes, including survival and clinical endpoints

Techniques, methods & infrastructure

Epidemiological and statistical modelling: application of time-to-event analysis, risk prediction models, interaction analysis to identify genetic and clinical modifiers of cancer risk and outcomes.

Variant interpretation frameworks: harmonization of classification and reporting methods based on ACMG and ENIGMA criteria; contributions to international reclassification efforts using real-world data.

Psychosocial research tools: validation and implemetation of standardized instruments (e.g. German Cancer Worry Scale) to assess psychological impact, screening decisions, and quality of life following genetic counseling and testing.

Collaborative infrastructure: coordination of local institutional registry for hereditary breast and ovarian cancers, as well as active leadership in international research networks (e.g. IBCCS, CIMBA), with a focus on national and international data harmonization, and interoperable data frameworks to support investigator-driven research.

Grants

Selected publications

  1. Reichl et al. Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. Journal of Personalized Medicine. 2021; 11(9):917. Available at: https://doi.org/10.3390/jpm11090917.
  2. Silvestri et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [published correction appears in JAMA Oncol. 2020 Nov 1;6(11):1815]. JAMA Oncol. 2020;6(8):1218-1230. Available at: https://doi.org/10.1001/jamaoncol.2020.2134.
  3. Kuchenbaecker et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. Available at: http://dx.doi.org/10.1001/jama.2017.7112.
  4. Buchanan et al. Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. J Clin Oncol. 2014;32(2):90-100. Available at: http://dx.doi.org/10.1200/JCO.2013.51.2129.
  5. Tan et al. Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 132(12), pp.2876–2883. Available at: http://dx.doi.org/10.1002/ijc.27978.